No Picture

Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal

Regulus Therapeutics just finished dosing patients in toxicity studies for its second-generation autosomal dominant polycystic kidney disease (ADPKD) candidate RGLS8429. Based on FDA discussions and data from a Phase Ib trial on original ADPKD candidat… […]